Kleo Pharmaceuticals Inc.

Nov 06, 2019

Kleo Pharmaceuticals Presents Preclinical Data Supporting Development of its CD38-ARM(TM), a Novel Immuno-therapeutic, at American Society of Hematology (ASH) Annual Meeting

Nov 04, 2019

Biohaven Statement Regarding Kleo Pharmaceuticals (Kleo): Thomas J. Lynch, Jr., MD, Appointed As Kleo Chairman Of The Board

Nov 04, 2019

Kleo Pharmaceuticals Appoints Thomas J. Lynch, Jr., MD, as Chairman of the Board

Oct 15, 2019

Kleo Pharmaceuticals to Present at 2019 BIO Investor Forum

Jun 18, 2019

Kleo Pharmaceuticals Announces a CD38 Targeting Antibody Recruiting Molecule (ARM(TM)) to Treat Multiple Myeloma as the First Clinical Candidate in its Partnership with PeptiDream

May 16, 2019

Kleo Pharmaceuticals to Present at Two Upcoming Industry Conferences

Feb 26, 2019

Kleo Pharmaceuticals to Present at the 2019 BIO Asia International Conference

Dec 20, 2018

Kleo Pharmaceuticals to Present at Biotech Showcase(TM) 2019 in San Francisco

Nov 13, 2018

Kleo Pharmaceuticals Secures $21 Million to Advance Novel Small Molecule Cancer Immunotherapies

Apr 05, 2018

Kleo Pharmaceuticals Selected to Present at Biotech Innovation Conference

Apr 03, 2018

Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer

Jul 18, 2017

PeptiDream and Kleo Pharmaceuticals Announce Collaboration Agreement to Develop Novel Immunotherapies for Oncology

Jun 09, 2017

Kleo Pharmaceuticals Inc. Appoints Douglas J. Manion M.D. as Chief Executive Officer